VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2014 | Exciting explosion of new drugs in CLL

Speaking to the European Medical Journal at the EHA 2014 meeting, Prof. John Gribben, St Barts Hospital, London, UK, outlines the explosion of new drugs now available for patients based on the increased understanding of CLL disease biology. He outlines the efficacy and safety results from the RESONATE trial with ibrutinib versus Ofatumumab, idelalisib versus rituximab monotherapy study, and data with ABT-199 as monotherapy and in combination with obinutuzumab/GA101. Prof Gribben also comments on resistance observed with ibrutinib.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter